In prostate and breast cancer patients, high RKIP expression coupled with low STAT3 levels has been associated with improved overall survival, underscoring RKIP’s role as a potential transcriptional suppressor of inflammation and modulator of oncogenic signaling pathways (59). The gene discussed is PEBP1; the disease is breast carcinoma.